Johnson & Johnson - Product Pipeline Review - Q2 2011

Global Markets Direct, August 2011, Pages: 370

Johnson & Johnson – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Johnson & Johnson - Product Pipeline Review - Q2 2011” provides data on the Johnson & Johnson’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Johnson & Johnson’s corporate website, SEC filings, investor presentations and featured press releases, both from Johnson & Johnson and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Johnson & Johnson - Brief Johnson & Johnson overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Johnson & Johnson human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Johnson & Johnson with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Johnson & Johnson’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Johnson & Johnson’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Johnson & Johnson in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Johnson & Johnson’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Johnson & Johnson.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Johnson & Johnson and identify potential opportunities in those areas.

List of Tables
List of Figures
Johnson & Johnson Snapshot
Johnson & Johnson – Research and Development Overview
Johnson & Johnson – Pipeline Review
Johnson & Johnson – Pipeline Products Glance
Johnson & Johnson – Drug Profiles
Johnson & Johnson – Pipeline Analysis
Johnson & Johnson – Recent Pipeline Updates
Johnson & Johnson - Dormant Projects
Johnson & Johnson - Discontinued Pipeline Products
Johnson & Johnson – Company Statement
Johnson & Johnson – Locations And Subsidiaries
Recent Developments
Financial Deals Landscape
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Johnson & Johnson – Pipeline by Therapy Area and Indication, 2011
Johnson & Johnson – Pipeline by Stage of Development, 2011
Johnson & Johnson – Monotherapy Products in Pipeline, 2011
Johnson & Johnson – Combination Treatment Modalities in Pipeline, 2011
Johnson & Johnson – Filed, 2011
Johnson & Johnson – Phase III, 2011
Johnson & Johnson - Phase II, 2011
Johnson & Johnson - Phase I, 2011
Johnson & Johnson - Pipeline By Therapeutic Class, 2011
Johnson & Johnson - Pipeline By Target, 2011
Johnson & Johnson – Pipeline By Route of Administration, 2011
Johnson & Johnson – Pipeline By Molecule Type, 2011
Johnson & Johnson – Recent Pipeline Updates, 2011
Johnson & Johnson - Dormant Developmental Projects, 2010
Johnson & Johnson - Discontinued Pipeline Products, 2010
Johnson & Johnson, Subsidiaries
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary by Region, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011
Johnson & Johnson, Deals Summary, 2004 to YTD 2011

List of Figures
Johnson & Johnson – Pipeline by Therapy Area and Indication, 2011
Johnson & Johnson – Pipeline by Stage of Development, 2011
Johnson & Johnson – Monotherapy Products in Pipeline, 2011
Johnson & Johnson – Combination Treatment Modalities in Pipeline, 2011
Johnson & Johnson – Pipeline By Therapeutic Class, 2011
Johnson & Johnson - Pipeline By Target, 2011
Johnson & Johnson – Pipeline By Route of Administration, 2011
Johnson & Johnson – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• Amazon - Point of Realization in 2013?
• Insight into Samsung Electronics' Notebook PC Business Model
• Ixia - Company Analysis
• Accenture - Profile - US